132 related articles for article (PubMed ID: 30659691)
1. Impact of tumor-associated macrophages and BRAF
Cho JW; Kim WW; Lee YM; Jeon MJ; Kim WG; Song DE; Park Y; Chung KW; Hong SJ; Sung TY
Head Neck; 2019 Mar; 41(3):686-691. PubMed ID: 30659691
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
3. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
4. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.
Qing W; Fang WY; Ye L; Shen LY; Zhang XF; Fei XC; Chen X; Wang WQ; Li XY; Xiao JC; Ning G
Thyroid; 2012 Sep; 22(9):905-10. PubMed ID: 22870901
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.
Ahn D; Park JS; Sohn JH; Kim JH; Park SK; Seo AN; Park JY
Auris Nasus Larynx; 2012 Apr; 39(2):198-203. PubMed ID: 21862261
[TBL] [Abstract][Full Text] [Related]
6. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
9. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
10. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
11. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
12. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
13. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
14. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
15. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
16. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
17. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
18. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
Zheng X; Wei S; Han Y; Li Y; Yu Y; Yun X; Ren X; Gao M
Ann Surg Oncol; 2013 Jul; 20(7):2266-73. PubMed ID: 23370668
[TBL] [Abstract][Full Text] [Related]
19. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
20. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]